CSB601 Chap.1 Quality Use of Medicines and Medicines Information
Quality Use of Medicines and Medicines Information
What this chapter sets up
Week 1 frames the whole unit around safe, evidence-based medicine decisions.
You meet Quality Use of Medicines as a working idea, see how Australia's 2022 National Medicines Policy organises access, standards, quality use and industry into four central pillars, and learn how regulation through the Therapeutic Goods Administration shows up on a pack as an AUST L, AUST L(A) or AUST R number.
Skills you will practise
The practical core is choosing the right information resource: eTG for condition-based first-line choices, AMH for medicine-level detail, eMIMSelite for product information, AusDI for interaction checking and counselling, and the PBS for subsidised brands.
The chapter closes with the national rules for writing medicines safely, from error-prone abbreviations to the twelve standards for dispensed labels.
What this chapter covers
- 01
Quality Use of Medicines principles
- 02
National Medicines Policy pillars
- 03
Choosing medicines information resources
- 04
TGA registration and AUST labels
- 05
Safe medicines terminology
- 06
Dispensed medicine label standards
Worked example · free
Route three clinical questions to the right resource
- 2Task (a) is a condition-level decision, so eTG fits: it states first-, second- and third-line choices for specific conditions and specific patients, which AMH and MIMS do not attempt.
- 2Task (b) is a medicine-level check, so AMH fits as the tertiary national formulary covering dose, contraindications, adverse effects and interactions; eMIMSelite Product Information can confirm product-specific detail.
- 2Task (c) needs a multi-drug interaction checker; run AusDI and the MIMS checker together and note where their outputs differ, because polypharmacy screening is expected to compare both.
Key terms
- Quality Use of Medicines
- A national objective in which medicines are selected wisely, chosen to suit the person and then used safely and effectively, with non-drug options considered first.
- Bioequivalence
- Bioequivalence is the property of a generic medicine that releases the same active ingredient to a comparable extent and at a comparable speed as the original brand.
- Australian Register of Therapeutic Goods
- The national register on which every medicine supplied in Australia must appear, shown on the pack as an AUST L, AUST L(A) or AUST R number.
- Adverse Drug Reaction
- A harmful and unintended response to a medicine occurring at doses normally used for prevention, diagnosis, treatment or modifying physiological function.
- Trailing Zero
- A zero written after a decimal point in a whole-number dose, banned because a dose such as 5.0 can be misread as 50.
Quality Use of Medicines and Medicines Information FAQ
Do I need to memorise every Poisons Standard schedule?
Ten schedules exist, but workshop activities concentrate on unscheduled products and Schedules 2, 3, 4 and 8 when you classify real packs. Be able to name those four confidently, recognise Schedule 8 as controlled drugs and Schedule 4 as prescription only, and know that the standard also covers labelling, storage and disposal of poisons across jurisdictions.
Is a generic medicine identical to the original brand?
Not in every detail. A generic must contain the same active ingredient and be shown bioequivalent, so the effect on the body is the same within accepted limits, yet colour, shape, fillers and even the dose form can change. Those differences explain why some people react to a lactose or gluten excipient, and why consistent branding is advised for warfarin.
Should a suspected adverse drug reaction be reported even without proof?
Yes. Reporting relies on suspicion rather than certainty, because pooled reports let the national regulator detect rare or unexpected reactions that trials miss. Health professionals, consumers and carers can all lodge a report online, and the MIMS database links through to the same reporting system, so documenting the reaction in the record and reporting it are separate duties.
Exam move
Start by drawing your own routing table: write ten clinical questions down one side and the resources across the top, then mark which resource answers each. Test it on one antidepressant and one diuretic by looking up indications, dose ranges and adverse-effect frequencies in each database, noting how AMH sorts reactions into common, infrequent and rare bands.
Next, learn the four NMP pillars word for word and keep the three-part QUM description separate from the four-adverb Canvas summary, since mixing them is an easy lost mark. For regulation, practise reading AUST numbers on packs at home and saying what evidence each implies.
Finish with a safe-writing drill: take ten handwritten-style orders, rewrite each using full units, no trailing zeros, acceptable frequency terms and numerals, then check yourself against the labelling standard's first seven standards. Revisit this chapter before every later topic, because the same resources and terminology recur in every case question.
Working through Quality Use of Medicines and Medicines Information in CSB601? Sia is AskSia’s AI Pharmacy tutor — ask any CSB601 Quality Use of Medicines and Medicines Information question and get a clear, step-by-step explanation grounded in how CSB601 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
